-
PDF
- Split View
-
Views
-
Cite
Cite
Lynn K Paul, Shawneen R Pazienza, Warren S Brown, Alexithymia and somatization in agenesis of the corpus callosum, Social Cognitive and Affective Neuroscience, Volume 16, Issue 10, October 2021, Pages 1071–1078, https://doi.org/10.1093/scan/nsab056
- Share Icon Share
Abstract
Deficient communication between the cerebral hemispheres is one of several prevailing neurobiological explanations for alexithymia and has been strongly supported by research on patients with commissurotomy. We examined self-reported symptoms of alexithymia in adults with agenesis of the corpus callosum (AgCC), a condition characterized by more subtle reductions in interhemispheric transfer than in commissurotomy. Sixteen adults with AgCC and full-scale intelligence quotient >80 were compared with 15 neurotypical controls group-matched for age and intelligence score. The AgCC group endorsed greater difficulty identifying and describing feelings and more vague physical symptoms than controls but similar levels of emotional experience and emotional coping. This finding of impaired emotional interpretation with intact emotional experience is consistent with findings in callosotomy patients, implicating the critical role of the corpus callosum in cognitive dimensions of emotion processing. Further study of alexithymia in AgCC using task-based measures may help clarify the nature of this relationship.
Introduction
Alexithymia is a formal construct that describes deficient emotional expressiveness characterized by difficulty identifying and expressing feelings, a tendency toward somatic complaints, concrete and externally oriented thinking style, and a lack of imaginative thinking (Nemia et al., 1976). Alexithymia is inversely related to emotional intelligence and to emotion-focused coping styles (Lumley et al., 2005; Velasco et al., 2006).
The variation of characteristics and symptom patterns in alexithymia may reflect a diversity of causes (Moriguchi et al., 2006). Some argue that there are two basic forms or dimensions of alexithymia: ‘cognitive’, characterized by deficiency in ability to identify and verbalize feelings, and ‘affective’, characterized by deficiencies in evaluating emotional experiences (Gazzaniga and LeDoux, 1978; Goerlich-Dobre et al., 2015). For example, difficulty identifying and describing feelings may result from a general deficit in the cognitive processing of emotions (Lumley et al., 2005). Whereas, difficulty identifying and describing feelings accompanied by a tendency toward somatic complaints (Sifneos, 1973; Lesser, 1981) may be caused by difficulty distinguishing bodily sensations related to emotional arousal, i.e. affective processing (Lumley et al., 2005).
The current study examined the hypothesis that alexithymia and associated symptoms of somatization may result from disconnection between cognitive and affective processing systems—specifically disconnection of right hemisphere systems specialized for processing emotion, and left hemisphere systems specialized for processing language (TenHouten et al., 1985, 1988).
Corpus callosum and verbal expression of emotion
Several lines of research suggest that interhemispheric transfer plays a critical role in emotion processing and expression, and, consequently, interhemispheric deficits contribute to alexithymia. For example, individuals with high alexithymia scores and no known brain abnormality reportedly have significantly slower reaction times than non-alexithymic individuals on tasks requiring interhemispheric transfer (Dewaraja and Sasaki, 1990; Parker et al., 1999) and are significantly less accurate on a cross-hand finger localization task that requires interhemispheric transfer (Zeitlin et al., 1989).
While these studies support an association between interhemispheric transfer deficits and alexithymia, studies of callosotomy patients (severed corpus callosum and intact anterior commissure) provide further clarity about the role of callosally mediated interhemispheric transfer in emotional expression. After callosotomy, information about an emotional stimulus presented to the left visual field did not transfer from the right hemisphere to the left, but the subjective emotional valuation did transfer (i.e. patients could provide an accurate emotional evaluation of an ‘unseen’ emotional stimulus; Gazzaniga and LeDoux, 1978). In daily life, individuals who had undergone commissurotomy had diminished ability to verbally express their emotions (alexithymia) and increased psychosomatic complaints consistent with the psychoanalytic understanding of somatization as a compensation for inability to express emotions (Hoppe and Bogen, 1977; TenHouten et al., 1988). Together, these investigators argued that the corpus callosum was necessary for transferring emotional ‘information’ between the hemispheres, but emotional ‘experience’ (evaluations) may transfer via the anterior commissure or other pathways. The emergence of alexithymia following callosotomy suggests that eliminating interhemispheric transfer via the corpus callosum may be ‘causally’ related to alexithymia, but what if callosally mediated interhemispheric transfer is absent from birth?
In adults with agenesis of the corpus callosum (AgCC), a congenital abnormality where the axons that form the corpus callosum fail to develop or cross the midline (Rakic and Yakovlev, 1968), the absence of callosal connections does not limit interhemispheric transfer as markedly as callosotomy during adulthood (Lassonde et al., 1991; Brown et al., 1999). Could development of neural mechanisms that compensate for absence of callosally mediated interhemispheric transfer prevent alexithymia in these individuals?
Agenesis of the corpus callosum
AgCC occurs in ~1 of every 4000 live births (Glass et al., 2008). It can result from a variety of toxic, genetic or vascular causes, but only 30–45% of individuals have identifiable causes for their AgCC diagnosis (Paul et al., 2007). Studying the sub-population of individuals for whom complete or partial AgCC is the primary neurological condition (‘Primary AgCC’; Brown and Paul, 2019)—that is, those without other brain abnormalities and who possess a full-scale intelligence quotient within the normal range [i.e. full-scale intelligence quotient (FSIQ) ≥80]—can help identify contributions of callosal interactions to higher cognitive and psychosocial capacities such as alexithymia.
According to Brown and Paul (2019), deficiency in interhemispheric transfer of complex sensory information and learning (e.g. Sauerwein and Lassonde, 1983; Brown et al., 1999) is one of three core symptoms of Primary AgCC. Individuals with AgCC typically exhibit greater interhemispheric transfer than individuals with a commissurotomy, but far less than neurotypical individuals (Lassonde et al., 1991; Brown et al., 1999). For example, poor interhemispheric transfer is evident in mild-to-moderate difficulties on tasks necessitating bimanual coordination of motor movements (e.g. Mueller et al., 2009) and on tasks that assess interhemispheric transfer of complex sensory information (e.g. Jeeves and Silver, 1988; Brown et al., 1999). The other two core neuropsychological deficiencies posited by Brown and Paul (2019) involve cognitive processing speed (Marco et al., 2012) and complex novel problem-solving (e.g. Fischer et al., 1992; Schieffer et al., 2000; Brown et al., 2012). These three core deficits, in turn, produce a pattern of mild-to-moderate neuropsychological and psychosocial deficits in Primary AgCC (reviewed by Siffredi et al., 2013; Brown and Paul, 2019). Among these secondary cognitive symptoms, individuals with Primary AgCC have impairments in response inhibition and switching (Marco et al., 2012), sustained attention and vigilance (Brown et al., 2020), encoding in list-learning (Erickson et al., 2014; Paul et al., 2016), and higher-order language skills (Paul et al., 2003; Brown et al., 2005a,b; Rehmel et al., 2016).
Laboratory studies of adults with Primary AgCC have also revealed impairments in cognitive processing of emotions. Specifically, they have found exhibited deficits in strategic understanding and use of interpersonal emotions (Anderson et al., 2017), poor identification of emotion in faces (Bridgman et al., 2014), diminished ability to imagine the emotional implications and consequences of alternative behavioral decisions (Young et al., 2019), and limitations imagining and inferring the mental, emotional and social states of others (Renteria-Vazquez et al., under review; Brown and Paul, 2000; Paul et al., 2004; Symington et al., 2010; Turk et al., 2010). Finally, when viewing emotionally arousing images, individuals with AgCC had significant skin-conductive responses that discriminated between emotions but provided unreliable ratings of emotional valence and arousal for each image (Paul et al., 2006). This outcome is consistent with theories suggesting that information about emotion can be divided into cognitive and affective dimensions (Goerlich-Dobre et al., 2015) and that the corpus callosum is necessary specifically for the cognitive processing of emotional information (Gazzaniga and LeDoux, 1978).
This pattern of emotion processing deficits suggests that despite developmental compensation and greater capacity for interhemispheric transfer, adults with AgCC are likely to exhibit alexithymia symptoms similar to those in adult callosotomy patients. Parent reports indicate alexithymia symptoms are common in children with AgCC—difficulty feeling or expressing their own emotions (O’Brien, 1994; Brown and Paul, 2000) and elevated rates of somatization (Badaruddin et al., 2007)—but very little is known about how adults with AgCC experience the emotional processing deficits observed in laboratory experiments or if those deficits are associated with other symptoms of alexithymia such as increased somatization and externally oriented thinking.
Aims of this research
The purpose of this study was to further investigate the relationship between callosally mediated interhemispheric transfer and alexithymia in adults with Primary AgCC, by examining their individual experiences of emotions. In addition to the Toronto Alexithymia Scale-20 (TAS-20; Bagby et al., 1994), participants completed questionnaires about current emotional experiences [Positive and Negative Affect Schedule (PANAS); Watson et al., 1988], emotion processing and emotion expression for coping [Emotion Approach Coping Scale (EACS); Stanton et al., 1994], experience of somatic symptoms and health problems [Symptom Checklist, SCL90-R; Derogatis, 1977, 1983: Rand 36-Item Health Survey 1.0 (RHS); Hays et al., 1993] and interpretation of physical symptoms [Symptom Interpretation Questionnaire (SIQ); Robbins and Kirmayer, 1991].
As seen in adult callosotomy patients and described in children with AgCC, we hypothesized that relative to controls, adults with AgCC would endorse greater alexithymia symptomology on the TAS-20, as well as increased reports of physical symptoms and psychological interpretation of physical symptoms. Although studies of adult callosotomy patients indicate that emotional evaluation is not dependent on callosal transfer, we hypothesized that in AgCC, callosal absence and associated cognitive symptoms of alexithymia experienced across the lifespan would interfere with processing affect and result in restricted emotional expression (i.e. reduced use of emotional coping and lower reported levels of positive affect and negative affect).
Methods
Participants
Participants included 16 individuals with AgCC (7 partial AgCC, 7 male, 7 right-handed) and 15 control participants (8 male, 12 right-handed). Groups were matched on age, FSIQ, verbal comprehension index (VCI) (see Table 1), as well as handedness, χ2 = 2.9, P = 0.08, and gender, χ2 = 0.03, P = 0.09 (with Yates correction).
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | Range . | M . | s.d. . | Range . | t . | P . | 95% CI . |
Age | 30.50 | 10.74 | 16–52 | 31.07 | 9.48 | 21–45 | 0.155 | 0.88 | −8.029, 6.896 |
FSIQ | 99.88 | 12.88 | 81–129 | 101.13 | 10.11 | 84–116 | 0.301 | 0.77 | −9.804, 7.287 |
VCI | 102.50 | 15.28 | 82–131 | 104.33 | 10.30 | 89–126 | 0.389 | 0.70 | −11.475, 7.808 |
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | Range . | M . | s.d. . | Range . | t . | P . | 95% CI . |
Age | 30.50 | 10.74 | 16–52 | 31.07 | 9.48 | 21–45 | 0.155 | 0.88 | −8.029, 6.896 |
FSIQ | 99.88 | 12.88 | 81–129 | 101.13 | 10.11 | 84–116 | 0.301 | 0.77 | −9.804, 7.287 |
VCI | 102.50 | 15.28 | 82–131 | 104.33 | 10.30 | 89–126 | 0.389 | 0.70 | −11.475, 7.808 |
Notes: M = mean; s.d. = standard deviation; FSIQ = full-scale intelligence quotient; VCI = verbal comprehension index; CI = confidence interval of difference between means.
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | Range . | M . | s.d. . | Range . | t . | P . | 95% CI . |
Age | 30.50 | 10.74 | 16–52 | 31.07 | 9.48 | 21–45 | 0.155 | 0.88 | −8.029, 6.896 |
FSIQ | 99.88 | 12.88 | 81–129 | 101.13 | 10.11 | 84–116 | 0.301 | 0.77 | −9.804, 7.287 |
VCI | 102.50 | 15.28 | 82–131 | 104.33 | 10.30 | 89–126 | 0.389 | 0.70 | −11.475, 7.808 |
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | Range . | M . | s.d. . | Range . | t . | P . | 95% CI . |
Age | 30.50 | 10.74 | 16–52 | 31.07 | 9.48 | 21–45 | 0.155 | 0.88 | −8.029, 6.896 |
FSIQ | 99.88 | 12.88 | 81–129 | 101.13 | 10.11 | 84–116 | 0.301 | 0.77 | −9.804, 7.287 |
VCI | 102.50 | 15.28 | 82–131 | 104.33 | 10.30 | 89–126 | 0.389 | 0.70 | −11.475, 7.808 |
Notes: M = mean; s.d. = standard deviation; FSIQ = full-scale intelligence quotient; VCI = verbal comprehension index; CI = confidence interval of difference between means.
Participants with AgCC were recruited through the National Organization for Disorders of the Corpus Callosum, referrals and participant-initiated contact. Control participants were recruited through online advertisements. To avoid confounding effects from limited general intellectual function, FSIQ ≥80 and 12+ years of education were required. Exclusionary criteria for all participants included English as a second language, intractable epilepsy, major central nervous system disorder other than AgCC and history of drug abuse, moderate-to-severe head injury or neurosurgery. AgCC diagnosis and presence of anterior commissure were confirmed through review of magnetic resonance imaging (MRI) scans. Three potential AgCC participants with other structural brain abnormalities (heterotopia) were excluded.
All participants were tested as a part of a larger research project, including determination of FSIQ and VCI using the Wechsler Adult Intelligence Scale-Third Edition (Wechsler, 1997). All participants read and signed an informed consent form prior to testing. This research was approved by the Human Subjects Review Committee at the Travis Research Institute, Fuller Graduate School of Psychology.
Instruments
TAS-20 (Bagby et al., 1994) is a 20-item self-report questionnaire that provides a global measure of alexithymia and three subscale scores: (i) Difficulty Describing Feelings, ability to communicate emotions to other people, (ii) Externally-Oriented Thinking, degree to which the individual focuses on external rather than internal experiences and (iii) Difficulty Identifying Feeling, ability to identify and describe emotions and to distinguish them from bodily sensations.
PANAS (Watson et al., 1988) measures self-ratings of how strongly an individual is experiencing 10 positive and 10 negative feelings at the time of assessment.
EACS (Stanton et al., 1994) uses self-reported frequency of 16 behaviors to assesses the extent to which emotional expression (e.g. ‘I let my emotions out’) or emotional processing (e.g. ‘I explore my emotions’) are typically used to cope with highly stressful situations. The items focus on active attempts to display and examine one’s emotions but do not ask about use of cognitive strategies to process emotion.
The somatization scale from SCL90-R (Derogatis, 1977, 1983) measures self-reported presence of 12 different physical symptoms during the past week.
SIQ (Robbins and Kirmayer, 1991) assesses self-reported presence of six somatic symptoms in the prior 3 months (prolonged headache, excessive sweating, sudden dizziness, dry mouth, heart pounding and fatigue), as well as likelihood of attributing these to psychological, environmental and physical causes.
RHS (Hays et al., 1993) is a self-report measure of eight factors: general health perception, physical functioning, role limitations due to physical health, role limitations due to emotional problems, social functioning, emotional/mental health, bodily pain and energy/fatigue.
Procedure
All measures were administered remotely via a survey production website. At a previously determined time, the administrator called and assisted each participant in accessing the online survey. Instructions were presented online and also read aloud by the administrator. To demonstrate task comprehension, participants read the first two items aloud and responded online before independently completing the remainder of the session. The administrator was available by phone throughout testing and called hourly to provide assistance. Participants called administrator upon completion.
Statistical comparisons were computed with SPSS. Mauchly’s test of sphericity was conducted for each analysis of variance (ANOVA), and in cases where sphericity was violated at P < 0.05, the Huynh–Feldt correction was used if epsilon was ≥0.75 and Greenhouse–Geisser was used if epsilon was <0.75. In exploratory analyses of subscales, adjustment for multiple comparisons was addressed with Bonferroni correction.
Results
Descriptive statistics for all measures are presented in Table 2.
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . | t . | df . | P . | CI . |
TAS-20 | ||||||||||
Total** | 49.5 | 13.74 | 42.69, 56.06 | 38.47 | 5.41 | 35.93, 40.87 | ||||
Describing+ | 14.00 | 5.01 | 11.88, 16.53 | 10.47 | 3.25 | 9.00, 12.07 | 2.31 | 29 | 0.028 | 0.41, 6.66 |
Identifying++ | 16.25 | 5.86 | 13.63, 19.13 | 10.73 | 3.28 | 9.17, 12.40 | 3.26 | 23.9 | 0.003 | 2.02, 9.01 |
Externally | 19.25 | 5.40 | 16.69, 21.97 | 17.27 | 3.55 | 15.60,19.13 | 1.20 | 29 | 0.24 | −1.40, 5.37 |
EACS | ||||||||||
Expression | 3.08 | 0.83 | 2.66, 3.48 | 3.20 | 0.55 | 2.88, 3.52 | −0.08 | 27 | 0.94 | −0.61, 0.56 |
Processing | 2.82 | 0.82 | 2.53, 3.33 | 3.27 | 0.68 | 2.89, 3.64 | −0.66 | 27 | 0.52 | −0.83, 0.43 |
PANAS | ||||||||||
Positive | 31.69 | 10.04 | 26.94, 36.56 | 30.57 | 10.36 | 25.25, 36.00 | 0.30 | 28 | 0.77 | −6.52, 8.75 |
Negative | 13.63 | 5.11 | 11.31, 16.03 | 13.93 | 7.65 | 10.46, 18.29 | −0.13 | 28 | 0.90 | −5.11, 4.51 |
SCL90-R** | 23.06 | 6.13 | 20.31, 26.13 | 16.00 | 3.82 | 14.25, 18.14 | 3.84 | 25.5 | 0.001 | 3.18, 10.95 |
SIQ | ||||||||||
Psychological* | 12.00 | 3.29 | 10.56, 13.56 | 9.87 | 2.17 | 8.87, 10.93 | 2.12 | 29 | 0.04 | 0.07, 4.19 |
Physical | 8.50 | 2.03 | 7.59, 9.50 | 7.87 | 2.00 | 7.00, 8.97 | 0.88 | 29 | 0.39 | −0.85, 2.11 |
Environmental | 15.00 | 3.41 | 13.31, 16.59 | 14.60 | 3.27 | 13.07, 16.20 | 0.33 | 29 | 0.74 | −2.05, 2.85 |
RHS | ||||||||||
Health percep. | 58.00 | 9.60 | 53.33, 62.67 | 59.60 | 8.69 | 54.20, 64.40 | 0.13 | 27 | 0.90 | −7.44, 8.44 |
Physical funct. | 87.67 | 18.60 | 77.00, 95.33 | 85.00 | 29.91 | 64.75, 97.75 | −0.20 | 27 | 0.85 | −18.69, 15.45 |
Physical lim. | 86.54 | 21.93 | 75.00, 96.15 | 87.50 | 24.30 | 71.25, 100.00 | −0.55 | 25 | 0.59 | −21.57, 12.50 |
Emotional lim. | 89.74 | 21.01 | 76.94, 100.00 | 90.00 | 31.62 | 70.00, 100.00 | −1.69 | 23 | 0.11 | −22.83, 2.31 |
Social funct. | 51.97 | 17.49 | 43.67, 61.10 | 88.75 | 19.94 | 75.63, 97.50 | −0.76 | 27 | 0.46 | −17.12, 7.91 |
Mental health | 66.13 | 22.42 | 55.07, 76.80 | 74.40 | 14.14 | 65.00, 82.00 | −1.31 | 27 | 0.20 | −23.90, 5.31 |
Body pain | 68.83 | 25.33 | 56.17, 81.42 | 81.25 | 13.76 | 72.63, 89.50 | −2.06 | 22.6 | 0.052 | −31.38, 0.12 |
Energy/fatigue | 53.67 | 18.75 | 44.33, 63.17 | 56.00 | 18.07 | 45.5, 66.00 | −0.52 | 27 | 0.61 | −18.99, 11.32 |
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . | t . | df . | P . | CI . |
TAS-20 | ||||||||||
Total** | 49.5 | 13.74 | 42.69, 56.06 | 38.47 | 5.41 | 35.93, 40.87 | ||||
Describing+ | 14.00 | 5.01 | 11.88, 16.53 | 10.47 | 3.25 | 9.00, 12.07 | 2.31 | 29 | 0.028 | 0.41, 6.66 |
Identifying++ | 16.25 | 5.86 | 13.63, 19.13 | 10.73 | 3.28 | 9.17, 12.40 | 3.26 | 23.9 | 0.003 | 2.02, 9.01 |
Externally | 19.25 | 5.40 | 16.69, 21.97 | 17.27 | 3.55 | 15.60,19.13 | 1.20 | 29 | 0.24 | −1.40, 5.37 |
EACS | ||||||||||
Expression | 3.08 | 0.83 | 2.66, 3.48 | 3.20 | 0.55 | 2.88, 3.52 | −0.08 | 27 | 0.94 | −0.61, 0.56 |
Processing | 2.82 | 0.82 | 2.53, 3.33 | 3.27 | 0.68 | 2.89, 3.64 | −0.66 | 27 | 0.52 | −0.83, 0.43 |
PANAS | ||||||||||
Positive | 31.69 | 10.04 | 26.94, 36.56 | 30.57 | 10.36 | 25.25, 36.00 | 0.30 | 28 | 0.77 | −6.52, 8.75 |
Negative | 13.63 | 5.11 | 11.31, 16.03 | 13.93 | 7.65 | 10.46, 18.29 | −0.13 | 28 | 0.90 | −5.11, 4.51 |
SCL90-R** | 23.06 | 6.13 | 20.31, 26.13 | 16.00 | 3.82 | 14.25, 18.14 | 3.84 | 25.5 | 0.001 | 3.18, 10.95 |
SIQ | ||||||||||
Psychological* | 12.00 | 3.29 | 10.56, 13.56 | 9.87 | 2.17 | 8.87, 10.93 | 2.12 | 29 | 0.04 | 0.07, 4.19 |
Physical | 8.50 | 2.03 | 7.59, 9.50 | 7.87 | 2.00 | 7.00, 8.97 | 0.88 | 29 | 0.39 | −0.85, 2.11 |
Environmental | 15.00 | 3.41 | 13.31, 16.59 | 14.60 | 3.27 | 13.07, 16.20 | 0.33 | 29 | 0.74 | −2.05, 2.85 |
RHS | ||||||||||
Health percep. | 58.00 | 9.60 | 53.33, 62.67 | 59.60 | 8.69 | 54.20, 64.40 | 0.13 | 27 | 0.90 | −7.44, 8.44 |
Physical funct. | 87.67 | 18.60 | 77.00, 95.33 | 85.00 | 29.91 | 64.75, 97.75 | −0.20 | 27 | 0.85 | −18.69, 15.45 |
Physical lim. | 86.54 | 21.93 | 75.00, 96.15 | 87.50 | 24.30 | 71.25, 100.00 | −0.55 | 25 | 0.59 | −21.57, 12.50 |
Emotional lim. | 89.74 | 21.01 | 76.94, 100.00 | 90.00 | 31.62 | 70.00, 100.00 | −1.69 | 23 | 0.11 | −22.83, 2.31 |
Social funct. | 51.97 | 17.49 | 43.67, 61.10 | 88.75 | 19.94 | 75.63, 97.50 | −0.76 | 27 | 0.46 | −17.12, 7.91 |
Mental health | 66.13 | 22.42 | 55.07, 76.80 | 74.40 | 14.14 | 65.00, 82.00 | −1.31 | 27 | 0.20 | −23.90, 5.31 |
Body pain | 68.83 | 25.33 | 56.17, 81.42 | 81.25 | 13.76 | 72.63, 89.50 | −2.06 | 22.6 | 0.052 | −31.38, 0.12 |
Energy/fatigue | 53.67 | 18.75 | 44.33, 63.17 | 56.00 | 18.07 | 45.5, 66.00 | −0.52 | 27 | 0.61 | −18.99, 11.32 |
Notes: *P < 0.05; **P < 0.01; +Padj < 0.05; ++Padj < 0.01; s.d. = standard deviation, bsCI = 95% confidence interval estimated from 1000 bootstrap samples with replacement; CI = 95% confidence interval of difference between means; TAS-20 = Toronto Alexithymia Scale; EACS = Emotion Approach Coping Scale; PANAS = Positive and Negative Affect Scale; SCL90-R = Symptom Checklist Somatization Scale; SIQ = Symptom Interpretation Questionnaire; RHS = Rand 36-Item Health Survey 1.0; percep. = perception; funct. = functioning; lim. = limitations.
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . | t . | df . | P . | CI . |
TAS-20 | ||||||||||
Total** | 49.5 | 13.74 | 42.69, 56.06 | 38.47 | 5.41 | 35.93, 40.87 | ||||
Describing+ | 14.00 | 5.01 | 11.88, 16.53 | 10.47 | 3.25 | 9.00, 12.07 | 2.31 | 29 | 0.028 | 0.41, 6.66 |
Identifying++ | 16.25 | 5.86 | 13.63, 19.13 | 10.73 | 3.28 | 9.17, 12.40 | 3.26 | 23.9 | 0.003 | 2.02, 9.01 |
Externally | 19.25 | 5.40 | 16.69, 21.97 | 17.27 | 3.55 | 15.60,19.13 | 1.20 | 29 | 0.24 | −1.40, 5.37 |
EACS | ||||||||||
Expression | 3.08 | 0.83 | 2.66, 3.48 | 3.20 | 0.55 | 2.88, 3.52 | −0.08 | 27 | 0.94 | −0.61, 0.56 |
Processing | 2.82 | 0.82 | 2.53, 3.33 | 3.27 | 0.68 | 2.89, 3.64 | −0.66 | 27 | 0.52 | −0.83, 0.43 |
PANAS | ||||||||||
Positive | 31.69 | 10.04 | 26.94, 36.56 | 30.57 | 10.36 | 25.25, 36.00 | 0.30 | 28 | 0.77 | −6.52, 8.75 |
Negative | 13.63 | 5.11 | 11.31, 16.03 | 13.93 | 7.65 | 10.46, 18.29 | −0.13 | 28 | 0.90 | −5.11, 4.51 |
SCL90-R** | 23.06 | 6.13 | 20.31, 26.13 | 16.00 | 3.82 | 14.25, 18.14 | 3.84 | 25.5 | 0.001 | 3.18, 10.95 |
SIQ | ||||||||||
Psychological* | 12.00 | 3.29 | 10.56, 13.56 | 9.87 | 2.17 | 8.87, 10.93 | 2.12 | 29 | 0.04 | 0.07, 4.19 |
Physical | 8.50 | 2.03 | 7.59, 9.50 | 7.87 | 2.00 | 7.00, 8.97 | 0.88 | 29 | 0.39 | −0.85, 2.11 |
Environmental | 15.00 | 3.41 | 13.31, 16.59 | 14.60 | 3.27 | 13.07, 16.20 | 0.33 | 29 | 0.74 | −2.05, 2.85 |
RHS | ||||||||||
Health percep. | 58.00 | 9.60 | 53.33, 62.67 | 59.60 | 8.69 | 54.20, 64.40 | 0.13 | 27 | 0.90 | −7.44, 8.44 |
Physical funct. | 87.67 | 18.60 | 77.00, 95.33 | 85.00 | 29.91 | 64.75, 97.75 | −0.20 | 27 | 0.85 | −18.69, 15.45 |
Physical lim. | 86.54 | 21.93 | 75.00, 96.15 | 87.50 | 24.30 | 71.25, 100.00 | −0.55 | 25 | 0.59 | −21.57, 12.50 |
Emotional lim. | 89.74 | 21.01 | 76.94, 100.00 | 90.00 | 31.62 | 70.00, 100.00 | −1.69 | 23 | 0.11 | −22.83, 2.31 |
Social funct. | 51.97 | 17.49 | 43.67, 61.10 | 88.75 | 19.94 | 75.63, 97.50 | −0.76 | 27 | 0.46 | −17.12, 7.91 |
Mental health | 66.13 | 22.42 | 55.07, 76.80 | 74.40 | 14.14 | 65.00, 82.00 | −1.31 | 27 | 0.20 | −23.90, 5.31 |
Body pain | 68.83 | 25.33 | 56.17, 81.42 | 81.25 | 13.76 | 72.63, 89.50 | −2.06 | 22.6 | 0.052 | −31.38, 0.12 |
Energy/fatigue | 53.67 | 18.75 | 44.33, 63.17 | 56.00 | 18.07 | 45.5, 66.00 | −0.52 | 27 | 0.61 | −18.99, 11.32 |
. | AgCC, n = 16 . | Control, n = 15 . | . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . | t . | df . | P . | CI . |
TAS-20 | ||||||||||
Total** | 49.5 | 13.74 | 42.69, 56.06 | 38.47 | 5.41 | 35.93, 40.87 | ||||
Describing+ | 14.00 | 5.01 | 11.88, 16.53 | 10.47 | 3.25 | 9.00, 12.07 | 2.31 | 29 | 0.028 | 0.41, 6.66 |
Identifying++ | 16.25 | 5.86 | 13.63, 19.13 | 10.73 | 3.28 | 9.17, 12.40 | 3.26 | 23.9 | 0.003 | 2.02, 9.01 |
Externally | 19.25 | 5.40 | 16.69, 21.97 | 17.27 | 3.55 | 15.60,19.13 | 1.20 | 29 | 0.24 | −1.40, 5.37 |
EACS | ||||||||||
Expression | 3.08 | 0.83 | 2.66, 3.48 | 3.20 | 0.55 | 2.88, 3.52 | −0.08 | 27 | 0.94 | −0.61, 0.56 |
Processing | 2.82 | 0.82 | 2.53, 3.33 | 3.27 | 0.68 | 2.89, 3.64 | −0.66 | 27 | 0.52 | −0.83, 0.43 |
PANAS | ||||||||||
Positive | 31.69 | 10.04 | 26.94, 36.56 | 30.57 | 10.36 | 25.25, 36.00 | 0.30 | 28 | 0.77 | −6.52, 8.75 |
Negative | 13.63 | 5.11 | 11.31, 16.03 | 13.93 | 7.65 | 10.46, 18.29 | −0.13 | 28 | 0.90 | −5.11, 4.51 |
SCL90-R** | 23.06 | 6.13 | 20.31, 26.13 | 16.00 | 3.82 | 14.25, 18.14 | 3.84 | 25.5 | 0.001 | 3.18, 10.95 |
SIQ | ||||||||||
Psychological* | 12.00 | 3.29 | 10.56, 13.56 | 9.87 | 2.17 | 8.87, 10.93 | 2.12 | 29 | 0.04 | 0.07, 4.19 |
Physical | 8.50 | 2.03 | 7.59, 9.50 | 7.87 | 2.00 | 7.00, 8.97 | 0.88 | 29 | 0.39 | −0.85, 2.11 |
Environmental | 15.00 | 3.41 | 13.31, 16.59 | 14.60 | 3.27 | 13.07, 16.20 | 0.33 | 29 | 0.74 | −2.05, 2.85 |
RHS | ||||||||||
Health percep. | 58.00 | 9.60 | 53.33, 62.67 | 59.60 | 8.69 | 54.20, 64.40 | 0.13 | 27 | 0.90 | −7.44, 8.44 |
Physical funct. | 87.67 | 18.60 | 77.00, 95.33 | 85.00 | 29.91 | 64.75, 97.75 | −0.20 | 27 | 0.85 | −18.69, 15.45 |
Physical lim. | 86.54 | 21.93 | 75.00, 96.15 | 87.50 | 24.30 | 71.25, 100.00 | −0.55 | 25 | 0.59 | −21.57, 12.50 |
Emotional lim. | 89.74 | 21.01 | 76.94, 100.00 | 90.00 | 31.62 | 70.00, 100.00 | −1.69 | 23 | 0.11 | −22.83, 2.31 |
Social funct. | 51.97 | 17.49 | 43.67, 61.10 | 88.75 | 19.94 | 75.63, 97.50 | −0.76 | 27 | 0.46 | −17.12, 7.91 |
Mental health | 66.13 | 22.42 | 55.07, 76.80 | 74.40 | 14.14 | 65.00, 82.00 | −1.31 | 27 | 0.20 | −23.90, 5.31 |
Body pain | 68.83 | 25.33 | 56.17, 81.42 | 81.25 | 13.76 | 72.63, 89.50 | −2.06 | 22.6 | 0.052 | −31.38, 0.12 |
Energy/fatigue | 53.67 | 18.75 | 44.33, 63.17 | 56.00 | 18.07 | 45.5, 66.00 | −0.52 | 27 | 0.61 | −18.99, 11.32 |
Notes: *P < 0.05; **P < 0.01; +Padj < 0.05; ++Padj < 0.01; s.d. = standard deviation, bsCI = 95% confidence interval estimated from 1000 bootstrap samples with replacement; CI = 95% confidence interval of difference between means; TAS-20 = Toronto Alexithymia Scale; EACS = Emotion Approach Coping Scale; PANAS = Positive and Negative Affect Scale; SCL90-R = Symptom Checklist Somatization Scale; SIQ = Symptom Interpretation Questionnaire; RHS = Rand 36-Item Health Survey 1.0; percep. = perception; funct. = functioning; lim. = limitations.
Toronto Alexithymia Scale-20
TAS-20 scores were higher in the AgCC group than the control group in a group-by-subscale repeated measures ANOVA, ηp2 = 0.225, F(1, 29) = 8.44, P = 0.007. ANOVA also revealed a significant difference across subscales, ηp2 = 0.46, F(1.7,48.54) = 25.07, P < 0.001, but not a significant interaction of group-by-subscale, ηp2 = 0.06, F(1.7, 48.54) = 1.95, P = 0.16. A significantly greater number of participants with AgCC exceeded the clinical cutoff score for alexithymia (n = 5) or possible alexithymia (n = 1) than control participants (n = 0), Χ2(1) = 5.59, P = 0.018.
In exploratory group comparisons of sub-scores, the AgCC group endorsed significantly more difficulty on Difficulty Identifying Feelings, d = 1.33, and Difficulty Describing Feelings, d = 0.86, but did not differ from controls on Externally Oriented Thinking, d = 0.45.
Emotional experience and expression (PANAS/EACS)
Although the AgCC group endorsed difficulty on the TAS-20, they did not differ from the control group on endorsement of positive d = 0.11, or negative, d = 0.05, emotional experiences at the time of testing (PANAS), nor did the AgCC group differ from controls on use of emotion expression and/or emotion processing for coping (repeated measures ANOVA of two EACS subtests: group, ηp2 = 0.007, F(1,27) = 0.199, P = 0.659; subtest, ηp2 = 0.039, F(1,27) = 1.10, P = 0.304; group-by-subtest interaction ηp2 = 0.012, F(1,27) = 0.339, P = 0.565).
Expressions of somatic symptoms (SCL90-R/RHS)
The AgCC group endorsed more vague somatic symptoms than the control group on the SCL90-R Somatization scale, d = 1.52, but did not differ significantly from controls on any of the eight factors from RHS. Although not significant following false discovery rate correction, the AgCC group endorsed less bodily pain than the control group, d = 0.87.
Attribution style (SIQ)
Group-by-attribution style (psychological, environmental or physical) repeated measures ANOVA revealed a significant main effect of attribution style, ηp2 = 0.84, F(2,28) = 70.71, P < 0.001, but no significant effects related to group (group, ηp2 = 0.06, F(1,29) = 1.87, P = 0.18; group-by-attribution style, ηp2 = 0.09, F(2,28) = 1.447, P = 0.25). Exploratory group comparisons of attribution style suggested greater rates of psychological attributions in the AgCC than control group, d = 0.79 (large effect size but not significant after Bonferroni correction), and no significant differences on physical and environmental attributions.
Discussion
The results of this study indicate that alexithymia is more common in adults with Primary AgCC than in controls matched on age, Intelligence Quotient (IQ) and handedness and provide further evidence that interhemispheric transfer deficits may result in a specific pattern of alexithymia. As hypothesized, participants with AgCC were more likely than controls to have difficulty identifying and describing their emotions and tended to report more vague physical symptoms in the absence of notable health problems and attribute psychological factors to their physical states more frequently than controls. However, in contrast to our hypothesis, they gave no indication of deficits in emotional experience. The AgCC and control groups endorsed similar levels of attention to emotions (i.e. balance of focus on external vs internal experiences), experience of positive and negative emotions at the time testing, and frequency of attempts to acknowledge, actively process and express emotions in response to stressful situations. As hypothesized, deficiencies in emotional expression and elevated use of somatization (i.e. ‘cognitive’ symptoms of alexithymia) continue from childhood (O’Brien, 1994; Badaruddin et al., 2007) into adulthood, and these symptoms are recognized by the individuals with AgCC themselves.
In summary, our findings support conclusions drawn from studies of adult callosotomy and commissurotomy patients (Gazzaniga and LeDoux, 1978; Goerlich-Dobre et al., 2015)—namely that the corpus callosum is necessary for transferring emotional ‘information’ between the hemispheres but not for processing emotional ‘experience’ (evaluations). Moreover, we offer evidence that neurodevelopmental mechanisms that compensate for absence of callosally mediated interhemispheric transfer do not facilitate transfer of emotional ‘information’ between the hemispheres and that, in contrast to our hypothesis, the presence of cognitive alexithymia during development does not interfere with recognition of emotional experience (i.e. ‘affective’ alexithymia).
Although dependence on self-report is a potential limitation of the current study, the pattern of emotional processing described by these participants with AgCC—impaired ability to describe emotions but intact capacity to experience them—is consistent with results from a study that directly measured physiological arousal. The prior study recorded typical skin-conductive responses in individuals with AgCC when viewing emotionally arousing images, but participants provided restricted/atypical verbal ratings of their emotional reaction to the images (Paul et al., 2006). Thus, both self-reports and direct assessment of physiological arousal indicate that individuals with AgCC have typical physiological experiences of emotions and engage with emotions in a typical manner, despite disruption in the cognitive assessment and/or verbal description of their emotions.
In individuals with AgCC, as in callosotomy patients (Gazzaniga and LeDoux, 1978), this pattern of alexithymia is hypothesized to result from the disconnection between cognitive and affective processing systems—specifically disconnection of right hemisphere systems specialized for processing emotion and left hemisphere systems specialized for processing language (TenHouten et al., 1985, 1988). Our findings are also consistent with the theory that left hemisphere serves as an ‘interpreter’ of one’s own affective states and other ambiguous information (Gazzaniga, 2000), and as a result of deficient interhemispheric transfer in AgCC, the interpreter receives inadequate or inaccurate information from throughout the brain.
However, in AgCC, we cannot rule out the potential contribution of extra-callosal structural abnormalities that commonly accompany callosal absence in AgCC (e.g. colpocephaly and the presence of Probst bundles) or microscopic brain abnormalities not visible in MRIs, e.g. low numbers of Von Economo neurons (Kaufman et al., 2008). Thus, while alexithymia and somatization in AgCC is most likely associated with callosal absence, consistent presence of some other undetected brain abnormality cannot entirely be ruled out on the basis of currently available data.
Due to the small sample size, we were unable to examine possible differences between participants with complete AgCC and those with partial AgCC. It is noteworthy that these subgroups did not differ in percent of participants with clinically elevated TAS scores (partial = 33%; complete = 30%). Additionally, for all variables in this study, the complete and partial AgCC groups had overlapping bootstrapped confidence intervals of the means (Table 3), suggesting that the current findings are not impacted by the presence of residual callosal connections. However, this certainly merits further investigation. Because partial AgCC is characterized by considerable variability in the pattern of interhemispheric connectivity of the remaining callosal fibers (Wahl et al., 2009), it may be informative to examine the relationship between alexithymia symptoms and connectivity patterns as assessed with diffusion and functional MRI.
Means, standard deviations, and confidence intervals by AgCC subgroup for all variables
. | cAgCC, n = 10 . | pAgCC, n = 6 . | ||||
---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . |
TAS-20 | ||||||
Total | 52.67 | 11.67 | 45.44, 59.67 | 45.67 | 17.50 | 33.33, 58.00 |
Describing feelings | 15 | 3.84 | 12.44, 17.22 | 12.67 | 6.89 | 7.67, 18.00 |
Identifying feelings | 16.67 | 5.34 | 13.44, 20.33 | 16.00 | 7.48 | 10.83, 21.67 |
Externally oriented | 21 | 5.68 | 17.33, 24.44 | 17.00 | 4.82 | 13.00, 20.00 |
EACS | ||||||
Expression | 3.02 | 0.76 | 2.50, 3.50 | 3.02 | 1.00 | 2.30, 3.75 |
Processing | 2.75 | 0.71 | 2.38, 3.25 | 3.00 | 0.89 | 2.33, 3.67 |
PANAS | ||||||
Positive | 33.44 | 9.40 | 27.56, 39.44 | 30.5 | 11.78 | 22.25, 38.50 |
Negative | 13.33 | 4.66 | 10.89, 16.39 | 12.00 | 3.10 | 10.33, 14.67 |
SCL90-R Health | 24.44 | 6.17 | 20.67, 28.11 | 21.33 | 6.62 | 16.83, 26.33 |
SIQ | ||||||
Psychological | 12.22 | 2.99 | 10.33, 14.00 | 10.67 | 2.94 | 8.67, 12.67 |
Physical | 8.44 | 1.81 | 7.44, 9.56 | 8.00 | 2.10 | 6.83, 9.67 |
Environmental | 15.11 | 3.18 | 13.22, 17.22 | 14.50 | 4.18 | 11.33, 17.17 |
RHS | ||||||
Health perception | 55.63 | 9.43 | 49.38, 61.25 | 59.17 | 9.70 | 51.67, 65.83 |
Physical functioning | 88.12 | 14.62 | 77.50, 96.25 | 85.00 | 25.10 | 65.00, 98.33 |
Physical limit. | 84.38 | 22.90 | 68.75, 98.44 | 87.5 | 25.00 | 62.50, 100.0 |
Emotional limit. | 87.71 | 26.23 | 66.66, 100.0 | 93.34 | 14.89 | 80.02, 100.0 |
Social functioning | 58.13 | 19.75 | 45.75, 72.06 | 44.00 | 13.16 | 35.42, 54.33 |
Mental health | 70.00 | 12.65 | 62.00, 77.50 | 62.00 | 33.63 | 37.00, 84.00 |
Body pain | 63.44 | 21.21 | 50.94, 77.50 | 70.83 | 30.36 | 50.00, 91.67 |
Energy and fatigue | 52.50 | 15.58 | 43.13, 64.38 | 53.33 | 24.83 | 34.17, 70.00 |
. | cAgCC, n = 10 . | pAgCC, n = 6 . | ||||
---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . |
TAS-20 | ||||||
Total | 52.67 | 11.67 | 45.44, 59.67 | 45.67 | 17.50 | 33.33, 58.00 |
Describing feelings | 15 | 3.84 | 12.44, 17.22 | 12.67 | 6.89 | 7.67, 18.00 |
Identifying feelings | 16.67 | 5.34 | 13.44, 20.33 | 16.00 | 7.48 | 10.83, 21.67 |
Externally oriented | 21 | 5.68 | 17.33, 24.44 | 17.00 | 4.82 | 13.00, 20.00 |
EACS | ||||||
Expression | 3.02 | 0.76 | 2.50, 3.50 | 3.02 | 1.00 | 2.30, 3.75 |
Processing | 2.75 | 0.71 | 2.38, 3.25 | 3.00 | 0.89 | 2.33, 3.67 |
PANAS | ||||||
Positive | 33.44 | 9.40 | 27.56, 39.44 | 30.5 | 11.78 | 22.25, 38.50 |
Negative | 13.33 | 4.66 | 10.89, 16.39 | 12.00 | 3.10 | 10.33, 14.67 |
SCL90-R Health | 24.44 | 6.17 | 20.67, 28.11 | 21.33 | 6.62 | 16.83, 26.33 |
SIQ | ||||||
Psychological | 12.22 | 2.99 | 10.33, 14.00 | 10.67 | 2.94 | 8.67, 12.67 |
Physical | 8.44 | 1.81 | 7.44, 9.56 | 8.00 | 2.10 | 6.83, 9.67 |
Environmental | 15.11 | 3.18 | 13.22, 17.22 | 14.50 | 4.18 | 11.33, 17.17 |
RHS | ||||||
Health perception | 55.63 | 9.43 | 49.38, 61.25 | 59.17 | 9.70 | 51.67, 65.83 |
Physical functioning | 88.12 | 14.62 | 77.50, 96.25 | 85.00 | 25.10 | 65.00, 98.33 |
Physical limit. | 84.38 | 22.90 | 68.75, 98.44 | 87.5 | 25.00 | 62.50, 100.0 |
Emotional limit. | 87.71 | 26.23 | 66.66, 100.0 | 93.34 | 14.89 | 80.02, 100.0 |
Social functioning | 58.13 | 19.75 | 45.75, 72.06 | 44.00 | 13.16 | 35.42, 54.33 |
Mental health | 70.00 | 12.65 | 62.00, 77.50 | 62.00 | 33.63 | 37.00, 84.00 |
Body pain | 63.44 | 21.21 | 50.94, 77.50 | 70.83 | 30.36 | 50.00, 91.67 |
Energy and fatigue | 52.50 | 15.58 | 43.13, 64.38 | 53.33 | 24.83 | 34.17, 70.00 |
Notes: s.d. = standard deviation; bsCI = 95% confidence interval estimated from 1000 bootstrap samples with replacement; TAS-20 = Toronto Alexithymia Scale; EACS = Emotion Approach Coping Scale; PANAS = Positive and Negative Affect Scales; SCL90-R = Symptom Checklist Somatization Scale; SIQ = Symptom Interpretation Questionnaire; RHS = Rand 36-Item Health Survey 1.0; limit. = limitations.
Means, standard deviations, and confidence intervals by AgCC subgroup for all variables
. | cAgCC, n = 10 . | pAgCC, n = 6 . | ||||
---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . |
TAS-20 | ||||||
Total | 52.67 | 11.67 | 45.44, 59.67 | 45.67 | 17.50 | 33.33, 58.00 |
Describing feelings | 15 | 3.84 | 12.44, 17.22 | 12.67 | 6.89 | 7.67, 18.00 |
Identifying feelings | 16.67 | 5.34 | 13.44, 20.33 | 16.00 | 7.48 | 10.83, 21.67 |
Externally oriented | 21 | 5.68 | 17.33, 24.44 | 17.00 | 4.82 | 13.00, 20.00 |
EACS | ||||||
Expression | 3.02 | 0.76 | 2.50, 3.50 | 3.02 | 1.00 | 2.30, 3.75 |
Processing | 2.75 | 0.71 | 2.38, 3.25 | 3.00 | 0.89 | 2.33, 3.67 |
PANAS | ||||||
Positive | 33.44 | 9.40 | 27.56, 39.44 | 30.5 | 11.78 | 22.25, 38.50 |
Negative | 13.33 | 4.66 | 10.89, 16.39 | 12.00 | 3.10 | 10.33, 14.67 |
SCL90-R Health | 24.44 | 6.17 | 20.67, 28.11 | 21.33 | 6.62 | 16.83, 26.33 |
SIQ | ||||||
Psychological | 12.22 | 2.99 | 10.33, 14.00 | 10.67 | 2.94 | 8.67, 12.67 |
Physical | 8.44 | 1.81 | 7.44, 9.56 | 8.00 | 2.10 | 6.83, 9.67 |
Environmental | 15.11 | 3.18 | 13.22, 17.22 | 14.50 | 4.18 | 11.33, 17.17 |
RHS | ||||||
Health perception | 55.63 | 9.43 | 49.38, 61.25 | 59.17 | 9.70 | 51.67, 65.83 |
Physical functioning | 88.12 | 14.62 | 77.50, 96.25 | 85.00 | 25.10 | 65.00, 98.33 |
Physical limit. | 84.38 | 22.90 | 68.75, 98.44 | 87.5 | 25.00 | 62.50, 100.0 |
Emotional limit. | 87.71 | 26.23 | 66.66, 100.0 | 93.34 | 14.89 | 80.02, 100.0 |
Social functioning | 58.13 | 19.75 | 45.75, 72.06 | 44.00 | 13.16 | 35.42, 54.33 |
Mental health | 70.00 | 12.65 | 62.00, 77.50 | 62.00 | 33.63 | 37.00, 84.00 |
Body pain | 63.44 | 21.21 | 50.94, 77.50 | 70.83 | 30.36 | 50.00, 91.67 |
Energy and fatigue | 52.50 | 15.58 | 43.13, 64.38 | 53.33 | 24.83 | 34.17, 70.00 |
. | cAgCC, n = 10 . | pAgCC, n = 6 . | ||||
---|---|---|---|---|---|---|
. | M . | s.d. . | bsCI . | M . | s.d. . | bsCI . |
TAS-20 | ||||||
Total | 52.67 | 11.67 | 45.44, 59.67 | 45.67 | 17.50 | 33.33, 58.00 |
Describing feelings | 15 | 3.84 | 12.44, 17.22 | 12.67 | 6.89 | 7.67, 18.00 |
Identifying feelings | 16.67 | 5.34 | 13.44, 20.33 | 16.00 | 7.48 | 10.83, 21.67 |
Externally oriented | 21 | 5.68 | 17.33, 24.44 | 17.00 | 4.82 | 13.00, 20.00 |
EACS | ||||||
Expression | 3.02 | 0.76 | 2.50, 3.50 | 3.02 | 1.00 | 2.30, 3.75 |
Processing | 2.75 | 0.71 | 2.38, 3.25 | 3.00 | 0.89 | 2.33, 3.67 |
PANAS | ||||||
Positive | 33.44 | 9.40 | 27.56, 39.44 | 30.5 | 11.78 | 22.25, 38.50 |
Negative | 13.33 | 4.66 | 10.89, 16.39 | 12.00 | 3.10 | 10.33, 14.67 |
SCL90-R Health | 24.44 | 6.17 | 20.67, 28.11 | 21.33 | 6.62 | 16.83, 26.33 |
SIQ | ||||||
Psychological | 12.22 | 2.99 | 10.33, 14.00 | 10.67 | 2.94 | 8.67, 12.67 |
Physical | 8.44 | 1.81 | 7.44, 9.56 | 8.00 | 2.10 | 6.83, 9.67 |
Environmental | 15.11 | 3.18 | 13.22, 17.22 | 14.50 | 4.18 | 11.33, 17.17 |
RHS | ||||||
Health perception | 55.63 | 9.43 | 49.38, 61.25 | 59.17 | 9.70 | 51.67, 65.83 |
Physical functioning | 88.12 | 14.62 | 77.50, 96.25 | 85.00 | 25.10 | 65.00, 98.33 |
Physical limit. | 84.38 | 22.90 | 68.75, 98.44 | 87.5 | 25.00 | 62.50, 100.0 |
Emotional limit. | 87.71 | 26.23 | 66.66, 100.0 | 93.34 | 14.89 | 80.02, 100.0 |
Social functioning | 58.13 | 19.75 | 45.75, 72.06 | 44.00 | 13.16 | 35.42, 54.33 |
Mental health | 70.00 | 12.65 | 62.00, 77.50 | 62.00 | 33.63 | 37.00, 84.00 |
Body pain | 63.44 | 21.21 | 50.94, 77.50 | 70.83 | 30.36 | 50.00, 91.67 |
Energy and fatigue | 52.50 | 15.58 | 43.13, 64.38 | 53.33 | 24.83 | 34.17, 70.00 |
Notes: s.d. = standard deviation; bsCI = 95% confidence interval estimated from 1000 bootstrap samples with replacement; TAS-20 = Toronto Alexithymia Scale; EACS = Emotion Approach Coping Scale; PANAS = Positive and Negative Affect Scales; SCL90-R = Symptom Checklist Somatization Scale; SIQ = Symptom Interpretation Questionnaire; RHS = Rand 36-Item Health Survey 1.0; limit. = limitations.
The corpus callosum and reductions in interhemispheric connectivity have been linked to a variety of developmental diagnosis (Paul, 2011). In comparison to other clinical populations, the rate of clinically diagnosable alexithymia in our AgCC group (31.25%) is lower than rates seen in individuals with autism (40%, Tani et al., 2004; 48.1%, Hill et al., 2004), chronic pain (53%, Cox et al., 1994) and eating disorder (61.3%, de Groot et al., 1995; 68.8%, Taylor et al., 1996) but comparable to rates of alexithymia reported in multiple sclerosis (30.6%, Chahraoui et al., 2008) and major depressive disorder (26.9%, Leweke et al., 2012). Thus, as seen on many other cognitive and psychosocial dimensions studied in AgCC, there is a clear and significant shift of the distribution toward disability, as well as notable overlap with the distribution of symptoms in other developmental, psychiatric and neurological populations.
The elevated likelihood of cognitive alexithymia in our sample of individuals with both complete and partial AgCC provides further evidence that the corpus callosum plays a critical role in cognitive processing of emotions. Future studies using direct assessment of alexithymia symptoms in AgCC examined over the lifespan and in comparison with individuals who have other developmental diagnoses may help clarify the role of interhemispheric connectivity in development of emotional processing and expression and generate new ideas for treating alexithymia.
Acknowledgements
The authors would like to thank Richard D. Lane for consulting during early phases of this study. Portions of this paper served as the doctoral dissertation of SP, at the Fuller Graduate School of Psychology.
Funding
LP is supported in part by grant no. 1 R15 HD33118-01A1 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Open practices statement
The data and materials for all experiments will be available at the International Research Consortium for the Corpus Callosum and Cerebral Connectivity (IRC5) and are currently available by contacting the corresponding author. None of the experiments was preregistered.
Conflict of interest
The authors declare no conflicts of interest.